GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Notes Receivable

Immuron (FRA:ANW) Notes Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Immuron Notes Receivable?

Immuron's Notes Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


Immuron Notes Receivable Historical Data

The historical data trend for Immuron's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Notes Receivable Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immuron Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Immuron Notes Receivable Related Terms

Thank you for viewing the detailed overview of Immuron's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (FRA:ANW) Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines